Education
About Us
Working with TipRanks
Follow Us
Danaher Corp. (DHR)
NYSE:DHR
Earnings Data
Report Date
Jul 29, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
1.64Last Year’s EPS
1.72Same Quarter Last Year
Strong Buy
Based on 16 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Apr 22, 2025
|% Change Since: 1.55%
|Next Earnings Date:Jul 29, 2025
Earnings Call Sentiment|Neutral
The earnings call reflects a balanced outlook with significant achievements in bioprocessing and strong cash flow generation. However, challenges persist in core revenue stagnation, Life Sciences segment decline, and geopolitical tensions affecting China operations.Company Guidance
During Danaher Corporation's First Quarter 2025 Earnings Results Conference Call, the company reported first-quarter revenues of $5.7 billion, with core revenue flat year-over-year. The gross profit margin increased by 100 basis points to 61.2%, while the adjusted operating profit margin decreased by 50 basis points to 29.6%. Adjusted diluted net earnings per share were $1.88, and free cash flow was $1.1 billion, resulting in a free cash flow to net income conversion ratio exceeding 110%. The company raised its full-year bioprocessing growth expectation to high-single digits, driven by robust consumables demand. However, life sciences guidance was adjusted to flat growth due to a softer academic and government market, particularly in the U.S., and volume-based procurement impacts in China. Danaher expects core revenue growth of approximately 3% for the full year, with a second-quarter adjusted operating profit margin target of around 25.5%. The company also initiated full-year adjusted EPS guidance between $7.60 and $7.75, emphasizing its strategic focus on innovation, customer support, and long-term shareholder value.Strong Start to Fiscal Year 2025
First-quarter revenue, earnings, and cash flow exceeded expectations, with revenue reaching $5.7 billion. Bioprocessing saw high-single-digit growth, and order books showed consistent positive momentum.
Bioprocessing Growth
Bioprocessing core revenue increased by 7% with low double-digit growth in consumables and commercial demand from large pharma and CDMO customers.
New Product Launches
Significant investments in long-term growth resulted in impactful product launches, including Cytiva's Xcellerex X-platform and Beckman Coulter Life Sciences' mosaic spectral detection module.
Strong Free Cash Flow
Generated $1.1 billion of free cash flow with a conversion ratio of more than 110%.
---
DHR Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
DHR Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 22, 2025 | $184.96 | $192.07 | +3.84% |
Jan 29, 2025 | $247.46 | $223.39 | -9.73% |
Oct 22, 2024 | $271.36 | $260.58 | -3.97% |
Jul 23, 2024 | $249.97 | $263.21 | +5.30% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Danaher Corp. (DHR) report earnings?
Danaher Corp. (DHR) is schdueled to report earning on Jul 29, 2025, TBA Not Confirmed.
What is Danaher Corp. (DHR) earnings time?
Danaher Corp. (DHR) earnings time is at Jul 29, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is DHR EPS forecast?
DHR EPS forecast for the fiscal quarter 2025 (Q2) is 1.64.
---
